title: Regulatory issues in the approval of new drugs for diabetes mellitus, dyslipidemia, and the metabolic syndrome.
authors.affiliation: Medpace, Inc., Cincinnati, Ohio, USA. j.isaacsohn@medpace.com
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Isaacsohn
authors.forename: August J
authors.initials: AJ
authors.lastname: Troendle
authors.forename: David G
authors.initials: DG
authors.lastname: Orloff
mesh_terms: D003920:Diabetes Mellitus / Q000188:drug therapy; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004335:Drug and Narcotic Control; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents